>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

APP +32.6% (also increases its share repurchase authorization by $2 bln), LYFT +23.9%, FRSH +19.6% (also authorizes new $400 mln share repurchase program), GH +19.2%, BROS +18.3%, ZG +13.5%, OPFI +12.6%, WAY +11.7%, MKSI +11.3%, EPAM +11%, UAA +10.3%, ELF +10.2%, MEOH +10%, ECG +9.6%, DCO +8.9%, ML +8.6%, MRNA +8.5%, ZIP +7.3%, ASPN +7.1%, UPWK +7% (also to acquire Objective AI, announces new $100 mln share repurchase auth), CPRX +6.9%, STRA +6.8%, BBSI +6.6%, MCK +6.4%, LZ +6.1%, ALNT +6%, QCOM +6% (also authorizes a new $15 bln stock repurchase plan; also files mixed shelf securities offering), CERT +5.9%, HUBS +5.8%, SRAD +5.8%, NVMI +5.6%, COHR +5.5%, ACMR +5.5%, AU +5.4%, CEVA +5.3%, VTLE +5.2%, LFST +5.2%, YETI +5.2%, TPR +5.2%, MRX +5.1%, CDRE +5%, INSW +5%, TGLS +5%, GOLF +4.6%, TTWO +4.5%, RAMP +4.5%, FSM +4.5%, GERN +4.4%, MODV +4.3%, GOOS +4.1%, HIMX +4%, REAX +3.9%, ENLC +3.8%, LTM +3.8%, MT +3.7%, LSPD +3.7%, NVGS +3.6%, VYX +3.6%, NXST +3.6%, CXW +3.5%, HCAT +3.5% (also to acquire Intraprise Health), SBGI +3.3%, TBLA +3.3%, CDE +3.2%, TPX +3.2%, NTLA +3.2%, HST +3.1%, HBI +3.1%, CRH +3%, ACIW +2.9%, PLTK +2.9%, RPRX +2.8%, VITL +2.8%, RCUS +2.5%, MTSI +2.5%, SEE +2.4%, AMED +2.3%, ARDT +2.3%, MXCT +2.3%, MUR +2.3%, LCII +2.3%, RLJ +2.2%, JAZZ +2%, GILD +1.9%, QGEN +1.9%, IMVT +1.8%, BKE +1.7% (Comps), MLTX +1.7%, SRPT +1.6%, VTRS +1.6%, ANSS +1.5%, KD +1.5%, BAK +1.5%, EYPT +1.5%, SITM +1.4%, TRP +1.4%, RNR +1.3% (also increases share repurchase auth to $750 mln), CLDX +1.3%, HAE +1.3%

Other news:

EBS +22.8% (brincidofovir will be included in a clinical trial)
SWTX +13.5% (announces that long-term efficacy and safety data from the Phase 3 DeFi trial of nirogacestat)
CDMO +11.7% (to be acquired for $12.50/sh by investment firms)
BBIO +2.5% (Viking Global (Andreas Halvorsen) affirmed 13.4% active stake)
PACB +2.3% (Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop)
IMVT +1.8% (reports development updates)